Enveric Hires Fish & Richardson To Defend IP Against Petition Claiming Its Patent Contains Claims Relevant To AbbVie’s $1.2B Bretisilocin Acquisition [Benzinga]
Wednesday, October 15, 2025 1 min read
Key Takeaway: Enveric Biosciences has engaged Fish and Richardson P.C. to defend its U.S. Patent No. 12,138,276 against a Post-Grant Review petition from Gilgamesh Pharmaceuticals. The patent concerns halogenated psilocybin derivatives and their applications. This move underscores Enveric's commitment to protecting its intellectual property amidst competitive pressures.
Price reaction · baseline $9.72 (2025-10-15T14:18:00.000Z) · hit during market hours · 1 other ENVB headline(s) in the window, move may be shared
day 0 close
+11.1%
day 1
-2.7%
day 3 · peak
-12%
Market Sentiment Analysis
POSITIVE FACTORS
Enveric is actively defending its intellectual property.
Hiring a reputable firm like Fish and Richardson indicates confidence.
The case highlights the significance of Enveric's patent in the industry.
Full Press Release Details
Enveric Biosciences recently announced that it has hired intellectual property powerhouse Fish and Richardson P.C. to contest a Post-Grant Review (PGR) petition filed by rival Gilgamesh Pharmaceuticals against Enveric’s issued U.S. Patent No. 12,138,276 (the ‘276 patent) titled, “Halogenated psilocybin derivatives and methods of using.”
Full Article >>
Frequently Asked Questions
What is the purpose of Enveric's patent defense?
Enveric is defending its patent against a petition claiming it overlaps with Gilgamesh's claims.
Who has Enveric hired for its patent defense?
Enveric has hired Fish and Richardson P.C. to contest the petition.
What is the focus of Enveric's patent?
The patent involves halogenated psilocybin derivatives and their methods of use.
Who filed the petition against Enveric's patent?
The petition was filed by rival Gilgamesh Pharmaceuticals.